Abstract 1172P
Background
While immunotherapy has improved the prognosis of metastatic melanoma patients, a minority of patients will have prolonged remission. Recent data have emphasized the role of the gut microbiome in response to immunotherapy; however, there is a discrepancy in defining the optimal microbiome. Although recent fecal microbial transplantation (FMT) trials only included patients with sustained response to immunotherapy, a mixed response was registered, with scarce data on the antimicrobial resistance of the donors. A thorough evaluation of the gut microbiome of potential FMT donors is warranted before future trials.
Methods
A shotgun metagenomic sequencing was performed on Illumina NextSeq 2000 platform on stool samples of metastatic melanoma patients with complete and sustained response to immunotherapy (N=15).
Results
The average age of patients was 61.0 (±12.2) years. Patients usually received immunotherapy in the first line (N=14, 93.3%), with an average time to complete response of 7.6 (± 4.6) months. Firmicutes were the most common phylum with a relative abundance of 62.1% ± 13.2, followed by the Bacteroidetes (31.7% ± 13.8). Protobacteria were present in all patients, ranging from 0.06-3.4%. On Class level, Clostridia were the most abundant (53.9% ± 10.4), followed by Bacteroidia (31.7% ± 13.8). Similar results were seen for the order level, while Lachnospiraceae were the most common family (30.2% ± 8.6) but ranged from 8.1 – 43.8%, followed by Ruminococcaceae (6.7% ± 14.0), and Bacteroidaceae (6.2% ± 11.6). Only 14 bacterial families were present in all patients (25.4%). On the genus level, Bacteroides had the highest relative abundance (11.6% ± 6.2), followed by Lachnospiraceae (10.1% ± 5.9), and Phocaeicola (6.2% ± 4.4). 377 different species were found, with six patients (40%) reporting no traces of the Akkermansia municiphila. Antimicrobial resistance was most commonly found for tetracyclines (63.3% ± 6.9), macrolide-lincosamine-streptogramin B (14.5% ± 7.9), and sulfonamide trimethoprim (4.4% ± 2.4).
Conclusions
Patients with complete and sustained response to immunotherapy exhibit a heterogeneous gut microbiome with common resistance to Tetracycline antibiotics.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Croatian Society of Medical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13